Insulin degludec (Tresiba ) ULTRA-LONG ACTING BASAL INSULIN * Andre McMahon PharmD Candidate, University of Florida College of Pharmacy Overview Approval status ...
Title: DIABETES Author: dboles Last modified by: Cory True Created Date: 4/24/2006 11:38:09 AM Document presentation format: On-screen Show (4:3) Company
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets. Enquiry @ http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-major-developed-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-market/enquire-about-report
$39.0 billion market for Type 2 Diabetes Mellitus Therapeutics in Major Developed industry to 2021. Browse the following link, for more information @ http://www.marketintelreports.com/report/gbihc366mr/type-2-diabetes-mellitus-therapeutics-in-major-developed-markets-to-2021--strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity.
RECENT ADVANCES IN DIABETES MELLITUS Nihal Thomas MD MNAMS DNB (Endo) FRACP (Endo) FRCP(Edin) Professor, Department of Endocrinology, Diabetes and Metabolism